What’s Next? Five Things To Look Out For In August
Q2 Results Dominate August Landscape
Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.
You may also be interested in...
Teva has announced a major strategic shift in Japan, with its Teva Takeda Pharma joint venture striking a deal to divest the majority of its traditional generics business to Nichi-Iko so that it can focus instead on complex generics and specialty products.
Roche’s biggest seller, Avastin, has fallen to biosimilar competition in Europe, with at least one company confirming launch to Generics Bulletin.
The market for biosimilar Avastin is set to form imminently, with two players holding final approvals from the European Commission waiting in the wings. In the coming days, the EMA’s Committee for Medicinal Products for Human Use is likely to issue an opinion on a further application.